Holen Sie sich die Stockscreener-App
40.05
2.69%
1.05
Faeth Therapeutics Inc Aktie (FTH) Neueste Nachrichten
FAETH THERAPEUTICS, INC : NEEDHAM INITIATES COVERAGE WITH BUY RATING; PRICE TARGET $56 - Bitget
Needham initiates Faeth Therapeutics stock with buy rating on cancer drug potential - Investing.com Canada
FTH Initiates Coverage On by Needham -- Buy Rating with $56 Pric - GuruFocus
Khosla Ventures Seed Associates D, Llc Net Worth (2026) - GuruFocus
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Why is Faeth Therapeutics stock surging today? By Investing.com - Investing.com Canada
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer - BioSpace
FDA grants fast track status to Faeth’s endometrial cancer drug - Investing.com
Faeth Therapeutics (FTH) Gains FDA Fast Track for Endometrial Ca - GuruFocus
FDA grants fast track status to Faeth’s endometrial cancer drug By Investing.com - Investing.com Canada
FTH: Faeth Therapeutics, Inc.Insider Transations - Zacks Investment Research
Faeth Therapeutics (FTH) investor Caligan reports 2.4% stake in 13G/A - Stock Titan
Faeth Therapeutics (FTH) investor Trails Edge reports 2.0% beneficial stake in 13G/A - Stock Titan
Faeth Therapeutics (FTH): Khosla Ventures group discloses 10.2% ownership stake - Stock Titan
Faeth Therapeutics, Inc. (NASDAQ: FTH) Share Price, FTH Stock News, FTH Share Price & Updates - Kalkine
PR News | On the Move: Finn Names Flach PartnerFri., Aug. 14, 2026 - O'Dwyer's PR
Faeth Therapeutics (FTH) investor group reports 0% ownership in amended 13G - Stock Titan
Faeth Therapeutics Strengthens Executive Team With Senior Leadership Appointments - TradingView
Faeth Therapeutics Adds Senior Leaders Ahead of PIKTOR Clinical Milestones - citybiz
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments - BioSpace
Faeth Therapeutics names two senior vice presidents - Investing.com
Faeth Therapeutics: PI3K Pathway Inhibitor With Key Data Catalyst In Play Intrigues (FTH) - Seeking Alpha
Faeth Therapeutics (FTH) holder files to sell 130K shares under Rule 144 - Stock Titan
Form 144 | Faeth Therapeutics(FTH.US) 10% Stockholder Proposes to Sell 3.64 Million in Common Stocks - Moomoo
FTH Reiterated by HC Wainwright & Co. -- Price Target Maintained at $60 - GuruFocus
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 7, 2026 - BioSpace
H.C. Wainwright Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Faeth Therapeutics Presents Pk/Pd Modeling That Informs Piktor Dose Selection in Ongoing Fth-Pik-201 Trial - marketscreener.com
Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference - Business Wire
Oppenheimer Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $60 - moomoo.com
Faeth Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
FTH Initiated Coverage by Jones Trading -- Rating Set to Buy - GuruFocus
Faeth Therapeutics (FTH) Advances Cancer Research with Merger an - GuruFocus
Faeth Therapeutics, Inc. Q2 2026: Net loss $(16.0M), EPS $(2.84) — 10-Q Summary - TradingView
Faeth Therapeutics Posts $16.0 Million Q2 Net Loss - Quiver Quantitative
Faeth Therapeutics reports $16.0M Q2 net loss, $186.4M cash and marketable securities - TradingView
FTH: Strong cash position and clinical progress with PIKTOR, topline data expected by year-end 2026 - TradingView
FTH: Net loss rose sharply to $186.2M due to acquisition costs; cash reserves stand at $186.4M - TradingView
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates - Business Wire
FAETH THERAPEUTICS, INC : JONESTRADING INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $55 - Bitget
FTH Initiated Coverage by Raymond James -- Rating Set to Outperf - GuruFocus
Faeth Therapeutics, Inc expected to post a loss of $3.62 a shareEarnings Preview - TradingView
Raymond James Initiates Faeth Therapeutics at Outperform - marketscreener.com
Faeth Therapeutics initiated with an Outperform at Raymond James - TipRanks
This Faeth Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - webull.com
Faeth Therapeutics' Experimental Cancer Drug Piktor Has Upside Potential, Oppenheimer Says - marketscreener.com
This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
FTH Initiates Coverage On by Oppenheimer -- Rating Set to Outper - GuruFocus
Faeth Therapeutics, Inc. (FTH) gains Khosla Ventures as reported 10% owner - Stock Titan
Faeth Therapeutics initiated with an Outperform at Oppenheimer - TipRanks
Oppenheimer initiates Faeth Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
Faeth Therapeutics Ord Shs (FTH) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
FTH|Faeth Therapeutics Ord Shs|Price:28.290|Chg%:+0.530 - TradingKey
Faeth Therapeutics Adopts Performance-Based Stock Option Plan - TipRanks
Faeth Therapeutics grants performance options to Anand Parikh, Christopher Gerry and Josiah Craver - TradingView
Faeth Therapeutics (FTH) grants CEO 398,018 performance-based options - Stock Titan
FTH Initiated Coverage by Citizens -- Price Target Announced at $51 - GuruFocus
Faeth Therapeutics initiated with an Outperform at Citizens - TipRanks
Citizens initiates Faeth Therapeutics stock at outperform, $51 target By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Intuitive Surgical (ISRG) and Faeth Therapeutics (FTH) - The Globe and Mail
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):